Home
The Department of Biomedicine

News archive for The Department of Biomedicine

The research laboratory for brain cancer immunology and therapy at the Department of Biomedicine has received the secretary general of the Brain-Tumour Society Rolf Ledal to discuss current and future research projects.
This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.
For the third time, the Faculty of Medicine organized a career day for its PhD candidates. NTNU sent representatives to learn from us.
In an article published in Aftenposten Viten, researcher Marte Innselset Flydal describes how she is planning to develop medicine for children suffering from the rare disease phenylketonuria.
Meg Veruki and Espen Hartveit from the Retinal Microcircuits Research Group at the Department of Biomedicine have been chosen to be the Visionaries of the Quarter for the European Vision Institute.
Researcher's Grand Prix-cadidate Illimar Hugo Rekand is working to keep us healthy. He is investigating new opportunities for making new medicines in a world where antibiotic resistance is an increasing challenge.
Welcome to a 2-days workshop 17.-18. Oct. with the Andor Academy team and Bitplane (Imaris) representatives.
The fall semester at the Department of Biomedicine presents many exciting national and international lecturers.
The post-synaptic protein Arc has been termed a master regulator of memory. In line with its homology to certain viral proteins, it has also been shown recently to form virus-like capsids. We have elucidated for the first time the 3D structure of full-length monomeric Arc.
Defense for the PhD degree at the University of Bergen, Lawrence Fred Sembajwe
Thanks to funding from the Faculty of Medicine MIC recently got a new confocal in house. It was installed before summer and is ready to use.
A range of psychiatric disorders have molecular similarities that modern diagnostic tools don't recognize. This shows an international study with 2 million participants. The K.G. Jebsen center for neuropsychiatric disorders has provided Norwegian data and analyses.
Injection of a genetically modified polio virus into the brain can give brain cancer patients several years more than normal treatment.

Pages